FUJIFILM Diosynth Biotechnologies expands its partnership with Novavax to manufacture COVID-19 Vaccine Candidate at its Billingham site


FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announce today that its site in Billingham, UK will manufacture antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

Billingham plans to begin production of the first batch at beginning of Q1, 2021.